BRD9 Degrader Compounds With Selective Proteasomal Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BRD9 inhibitors exhibit poor efficacy and limited therapeutic window, necessitating the development of compounds that can efficiently degrade BRD9 across various cellular systems with improved profiles suitable for drug development.
Innovation Solution
Novel compounds designed to selectively degrade BRD9 through proteasomal degradation, utilizing a BRD9 binding ligand that targets the protein for degradation by the proteasome, with low hepatic clearance rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRD9 inhibitors are developed to treat cancer, then therapeutic efficacy is improved, but off-target effects and toxicity increase due to impact on normal physiological functions
Solution Approach 1:
The patent segments the broad BRD4 inhibition function into more specific sub-targets within the bromodomain family. By designing inhibitors that selectively target particular bromodomain-containing proteins involved in cancer pathways while sparing those critical for normal physiology, the patent reduces off-target effects. This is achieved through structure-based design that exploits subtle differences in binding pockets across bromodomain family members.
Solution Approach 2:
The patent applies local quality by modifying specific regions of the inhibitor molecule to enhance selectivity for cancer-relevant bromodomain targets. Through rational drug design, particular functional groups and molecular features are optimized to interact with specific amino acid residues in the target binding site, thereby improving efficacy against cancer cells while minimizing interaction with proteins involved in normal physiological processes.
2Object-affected harmful factors
If BRD9 inhibitors are designed for high selectivity, then off-target effects are reduced, but therapeutic efficacy across diverse cellular systems is limited
Solution Approach 1:
The patent employs structure-based drug design to create inhibitors with optimized pharmacokinetic and pharmacodynamic properties that enable broad efficacy across diverse cellular systems. The molecular structures are designed to maintain consistent binding affinity and degradation activity across different cell types and cancer models, achieving a balance between selectivity and universal therapeutic effectiveness.
Solution Approach 2:
The patent utilizes parameter changes by systematically optimizing molecular properties such as lipophilicity, molecular weight, and functional group composition to enhance both selectivity and efficacy. Through iterative structure-activity relationship studies, the patent identifies optimal parameter ranges that enable inhibitors to achieve high selectivity for BRD9 while maintaining potent therapeutic activity across various cellular contexts.
3Reliability
If current BRD9 inhibitors are used, then some degradation activity is achieved, but the therapeutic window is limited due to poor efficacy and toxicity
Solution Approach 1:
The patent employs structure-based design to create optimized copies of BRD9 inhibitor molecules with improved properties. By analyzing the binding mode and degradation mechanism of initial compounds, the patent designs subsequent generations of inhibitors that replicate and enhance the desired therapeutic effects while reducing toxicities, thereby expanding the therapeutic window through iterative molecular optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade BRD9, offering potent pharmacology and improved therapeutic potential with reduced side effects, demonstrating efficacy in preclinical cancer models.
Implementation Method 1
Novel compounds designed to selectively degrade BRD9 through proteasomal degradation
Data Source
AI summary
This disclosure provides a compound of formula (III):or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein the substituents are as defined herein. The disclosure also provides pharmaceutical compositions comprising said compounds and the use of said compounds in the treatment of diseases, e.g. cancer.